Clinical significance of loss of heterozygosity for M6P/IGF2R in patients with primary hepatocellular carcinoma.
OBJECTIVE
To investigate the relationship between loss of heterozygosity (LOH) for mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) and the outcomes for primary HCC patients treated with partial hepatectomy.


METHODS
The LOH for M6P/IGF2R in primary HCC patients was assessed using six different gene-specific nucleotide polymorphisms. The patients studied were enrolled to undergo partial hepatectomy.


RESULTS
M6P/IGF2R was found to be polymorphic in 73.3% (22/30) of the patients, and of these patients, 50.0% (11/22) had tumors showing LOH in M6P/IGF2R. Loss of heterozygosity in M6P/IGF2R was associated with significant reductions in the two year overall survival rate (24.9% vs 65.5%; P=0.04) and the disease-free survival rate (17.8% vs 59.3%; P=0.03).


CONCLUSIONS
These results show M6P/IGF2R LOH predicts poor clinical outcomes in surgically resected primary HCC patients.
Jang
Hong Seok
HS
Department of Radiation Oncology, The Catholic University of Korea, School of Medicine, Seoul, Korea.
Kang
Ki Mun
KM
Choi
Byung Ock
BO
Chai
Gyu Young
GY
Hong
Soon Chan
SC
Ha
Woo Song
WS
Jirtle
Randy L
RL
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics*; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000235:genetics* / Q000601:surgery; D005260:Female; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000601:surgery; D019656:Loss of Heterozygosity / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic / Q000235:genetics; D011237:Predictive Value of Tests; D011379:Prognosis; D017527:Receptor, IGF Type 2 / Q000235:genetics*; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D017527:Receptor, IGF Type 2